HemoSavin Pharma
Revolutionizing Hemophilia.
HemoSavin Pharmaceuticals is a preclinical stage company focused on commercializing The First Oral Small Molecule Treatment for Hemophilia A.
HemoSavin Pharmaceuticals is a preclinical stage company focused on commercializing The First Oral Small Molecule Treatment for Hemophilia A.
No Child Left Bleeding in The World
Significant Improvement in Clotting Parameters for Hemophilia A (HA), Mouse Dog, Human plasma and ex-vivo Human Blood Studies
1. Tail-clip studies done in oral in-vivo Hemophilia A mouse model 2. In-vivo Hemophilia A human plasma 3. In-vivo Hemophilia A canine plasma 4. Patient side ex-vivo human Hemophilia A blood
Hemophilia A is a $12.5B/yr Problem Globally (US$59M UAE)
Current solutions are far from perfect and better therapies are needed
The core and advisory team has expertise across the entire development roadmap
President/CTO
Inventor of HemoSavin. Author of 287 global and 61 US patents. 21+ years of experience in high-technology business and intellectual property.
Science Officer
Operations experience in biologics manufacturing. Implementation experience in marketing. Project management and entrepreneurship at Innosphere Ventures.
Preclinical Advisor
Chair Professor of Pediatrics and Pathology at The University of Michigan. Medical Director of the Pediatric in Hemophilia and Coagulation Disorders Program and the Special Coagulation Laboratory.
Preclinical Advisor
20+ years of experience in drug metabolism and pharmacokinetics (DMPK). Completed DMPK studies of INCIVEKTM and KALYDECOTM.
FDA/Clinical Advisor
25+ years of executive and consultancy experience in biotechnology. Successfully filed 36 FDA Orphan Drug Designation (ODD), Investigational New Drug (IND), and New Drug (NDA) Applications.
HemoSavin Pharma's research poster has been accepted for presentation at the Bleeding Disorders Conference in Atlanta, taking place this September.
HemoSavin Pharma anncounced the first oral small molecule therapy for Hemophilia at ISTH 2024.